AR067331A1 - PHARMACEUTICAL COMPOSITION DOSAGE FORM. NEW METHODS TO MASK FLAVOR - Google Patents

PHARMACEUTICAL COMPOSITION DOSAGE FORM. NEW METHODS TO MASK FLAVOR

Info

Publication number
AR067331A1
AR067331A1 ARP080102531A ARP080102531A AR067331A1 AR 067331 A1 AR067331 A1 AR 067331A1 AR P080102531 A ARP080102531 A AR P080102531A AR P080102531 A ARP080102531 A AR P080102531A AR 067331 A1 AR067331 A1 AR 067331A1
Authority
AR
Argentina
Prior art keywords
parasympathetic
poly
acid
agents
pharmaceutical composition
Prior art date
Application number
ARP080102531A
Other languages
Spanish (es)
Inventor
Brian Becicka
Erik Michalson
Original Assignee
Cambrex Charles City Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambrex Charles City Inc filed Critical Cambrex Charles City Inc
Publication of AR067331A1 publication Critical patent/AR067331A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Composicion farmacéutica con sabor enmascarado adecuada para su administracion oral, que comprende una mezcla granulada de un ingrediente farmacéutico activo y un componente de microesferas porosas, en el cual el ingrediente activo farmacéutico está incorporado en los poros de las microesferas porosas. Mctodo de tratamiento. Proceso. Reivindicacion 4: La composicion farmacéutica con sabor enmascarado de la reivindicacion 1 o 2, donde el componente de microesferas porosas se selecciona del grupo que consiste en poliésteres, poliamidas, polianhedridos, y poliacrilatos, ácido poli(láctico), ácido: poli(glicolico), ácido copoli(láctico/glicolico) y poli[ácido 1,3-bis(-p-carboxifenoxi)propan-co-sebácico], ácido poliglicolico (PGA) o poliláctico (PLA), copolemeros de glicolido y L(-láctido) (PGL), gelatina, agar, almidon, arabinogalactano, albumina, colágeno, materiales o polímeros naturales y sintéticos, tales como poli(epsilon-caprolactona), poli(epsilon-caprolactona-CO-ácido láctico), poli(epsilon-caprolactona-CO-ácido glicolico), poli(ácido beta-hidroxi buterico), oxido de polietileno, polietileno, poli(alquil-2-cianoacrilato) (por ejemplo, metil-, etil-, butil-2-cianoacrilato, etcétera), hidrogeles, tales como poli(metacrilato de hidroxietilo), poliamidas (por ejemplo, poliacrilamida), poli(arninoácidos) (es decir, L-leucina, L-ácido aspártico, beta-metil-L-aspartato, beta-bencil-L-aspartato, ácido glutámico, y semejantes), poli(2-hidroxietil DL-aspartamida), poli(éster de urea), poli(L- fenilalanina/etilenglicol/1,6-diisocianatohexano), poli(metacrilato de metilo), SephadexTM, SepharoseTM, y SuperoseTM, TrisacrilTM, UltrogelTM, medios ACATM, GF05TM y GF2000TM, medios SephacrilTM, medios SuperdexTM, tales como Superdex 75TM y Superdex 200TM, variantes de éstos, y combinaciones de éstos. Reivindicacion 5: La composicion farmacéutica con sabor enmascarado de la reivindicacion 1 o 2, donde el API se selecciona entre antibioticos, agentes antivirales, analgésicos, anestésicos, anoréxicos, antiartríticos, agentes antiasmáticos, anticonvulsivos, antidepresivos, agentes antidiabéticos, antidiarreicos, antihistamenicos, agentes antiinflamatorio, antinauseantes, antineoplásticos, drogas antiparkinsonismo, antiprureticos, antipsicnticos, antipiréticos, antiespasmodicos, antagonistas H2, antitusígenos, drogas cardiovasculares, antiarrítmicos, antihipertensivos, inhibidores de la ACE, diuréticos, vasodilatadores, hormonas, hipnoticos, inmunosupresores, relajantes musculares, parasimpatolíticos, parasimpátomiméticos, psicoestimulante, sedantes, agentes antimigrana, agentes antituberculosis, tranquilizantes, vitaminas y suplementos minerales. Reivindicacion 12: Una forma de dosificacion farmacéutica individual que comprende un complejo de API-microesferas porosas, donde la forma de dosificacion está recubierta con un recubrimiento aceptable para el uso farmacéutico. Reivindicacion 21: Una composicion farmacéutica que comprende un complejo de API-microesferas porosas, y que opcionalmente comprende además al menos un saborizante, y/o al menos un edulcorante, y/o al menos un recubrimiento.Pharmaceutical composition with masked flavor suitable for oral administration, comprising a granulated mixture of an active pharmaceutical ingredient and a porous microsphere component, in which the pharmaceutical active ingredient is incorporated into the pores of the porous microspheres. Method of treatment Process. Claim 4: The masked flavor pharmaceutical composition of claim 1 or 2, wherein the porous microsphere component is selected from the group consisting of polyesters, polyamides, polyanhedides, and polyacrylates, poly (lactic acid), acid: poly (glycolic) , copoly (lactic / glycolic acid) and poly [1,3-bis (-p-carboxyphenoxy) propan-co-sebacic acid], polyglycolic acid (PGA) or polylactic acid (PLA), glycolide co-polymers and L (-lactide) (PGL), gelatin, agar, starch, arabinogalactan, albumin, collagen, natural and synthetic materials or polymers, such as poly (epsilon-caprolactone), poly (epsilon-caprolactone-CO-lactic acid), poly (epsilon-caprolactone- CO-glycolic acid), poly (beta-hydroxy buteric acid), polyethylene oxide, polyethylene, poly (alkyl-2-cyanoacrylate) (for example, methyl-, ethyl-, butyl-2-cyanoacrylate, etc.), hydrogels, such as poly (hydroxyethyl methacrylate), polyamides (eg, polyacrylamide), poly (arnin oacids) (i.e., L-leucine, L-aspartic acid, beta-methyl-L-aspartate, beta-benzyl-L-aspartate, glutamic acid, and the like), poly (2-hydroxyethyl DL-aspartamide), poly ( urea ester), poly (L-phenylalanine / ethylene glycol / 1,6-diisocyanatohexane), poly (methyl methacrylate), SephadexTM, SepharoseTM, and SuperoseTM, TrisacrilTM, UltrogelTM, ACATM media, GF05TM and GF2000TM, SephacrilTM media, SuperdexTM media , such as Superdex 75TM and Superdex 200TM, variants thereof, and combinations thereof. Claim 5: The pharmaceutical composition with masked flavor of claim 1 or 2, wherein the API is selected from antibiotics, antiviral agents, analgesics, anesthetics, anorexics, antiarthritics, anti-asthmatic agents, anticonvulsants, antidepressants, anti-diabetic agents, anti-diarrheal agents, antihistamenic agents anti-inflammatory, anti-nauseating, anti-neoplastic drugs, anti-Parkinsonism, anti-purrotic, antipsychotic, antipyretic, antispasmodic, H2 antagonist, antitussive, cardiovascular drug, antiarrhythmic, antihypertensive, ACE inhibitors, diuretic, vasodilator, parasympathetic, muscle-parasympathetic, parasympathetic, parasympathetic, parasympathetic, parasympathetic, parasympathetic, parasympathetic, parasympathetic, parasympathetic, muscle, parasympathetic, parasympathetic, parasympathetic, parasympathetic, musculoskeletal, parasympathetic , psychostimulant, sedatives, antimigrane agents, antituberculosis agents, tranquilizers, vitamins and mineral supplements. Claim 12: An individual pharmaceutical dosage form comprising a complex of porous API-microspheres, wherein the dosage form is coated with a coating acceptable for pharmaceutical use. Claim 21: A pharmaceutical composition comprising a complex of porous API-microspheres, and optionally further comprising at least one flavor, and / or at least one sweetener, and / or at least one coating.

ARP080102531A 2007-06-13 2008-06-13 PHARMACEUTICAL COMPOSITION DOSAGE FORM. NEW METHODS TO MASK FLAVOR AR067331A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94366607P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
AR067331A1 true AR067331A1 (en) 2009-10-07

Family

ID=40156604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102531A AR067331A1 (en) 2007-06-13 2008-06-13 PHARMACEUTICAL COMPOSITION DOSAGE FORM. NEW METHODS TO MASK FLAVOR

Country Status (2)

Country Link
AR (1) AR067331A1 (en)
WO (1) WO2008157228A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2874824A1 (en) 2012-07-23 2015-05-27 Crayola LLC Dissolvable films and methods of using the same
CN102988546A (en) * 2012-11-21 2013-03-27 徐曼丽 Traditional Chinese medicine sachet used for refreshing
CN105866308A (en) * 2016-05-10 2016-08-17 芜湖雨耕山食品检测有限公司 Method of utilizing gas chromatography to detect cyclamate
EP3251661B1 (en) 2016-05-30 2020-12-23 Sun Pharmaceutical Industries Limited Raloxifene sprinkle composition
CN107083180B (en) * 2017-05-25 2020-05-05 江南大学 Self-cleaning reflective coating based on strawberry-type microspheres and preparation method thereof
CN112315944B (en) * 2020-12-08 2022-09-02 黄山中皇制药有限公司 Preparation method of potassium dehydroandrographolide succinate enteric dry suspension

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
WO2005013944A1 (en) * 2003-08-11 2005-02-17 Merck Frosst Canada Ltd. Flavored taste-masked pharmaceutical formulation made using a one-step coating process

Also Published As

Publication number Publication date
WO2008157228A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
AR067331A1 (en) PHARMACEUTICAL COMPOSITION DOSAGE FORM. NEW METHODS TO MASK FLAVOR
ES2718688T3 (en) Tamper-resistant dosage form for oxidation-sensitive opioids
ES2270335T3 (en) PHARMACEUTICAL COMPOSITION OF FAST EFFECT.
HRP20191909T1 (en) Novel and potent tapentadol dosage forms
ES2528282T3 (en) Composition and microsphere for controlled release of exendin, and method for its preparation
JP2017509677A (en) Organic compounds
JP2013516403A5 (en)
JP2004155791A5 (en)
CL2004000889A1 (en) COMPOUNDS DERIVED FROM PIRAZOLO [4,3-d] PYRIMIDINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HYPERTENSION.
AR031853A1 (en) BICYCLE DERIVATIVES OF AMINO ACIDS WITH BRIDGE AZA, PROCESS TO PREPARE A BROKER, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USE OF SUCH DERIVATIVES IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT INTEGRATED MEDIATION DISORDERS
CN103547260A (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a CNS disorder
HUP0301822A2 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migrains
EP2316490A3 (en) Methods and compositions for enhanced delivery of bioactive molecules
CN103619910A (en) New biodegradable polyesteramide copolymers for drug delivery
CO6290716A2 (en) DEVICES THAT DELIVER BASIC AMINO ACIDS TO ORAL CAVITY
Jiang et al. Development of chondroitin sulfate encapsulated PLGA microsphere delivery systems with controllable multiple burst releases for treating osteoarthritis
CN110582268A (en) extruded depot dosage forms for sustained release of active ingredients
PA8579801A1 (en) PHARMACEUTICAL COMPOSITIONS OF SEMIORDENED AND POLYMER DRUGS
CN101415426A (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW201726118A (en) Microneedle sheet
US20130202685A1 (en) Use of a histamine H4 antagonist for the treatment of post-operative adhesions
EP3452031A1 (en) Precision controlled load and release particles for post-operative pain
FR2854159B1 (en) NOVEL INDOLE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS KDR INHIBITORS
US20110184057A1 (en) Parenteral treatment with statins
BRPI0714818A2 (en) subcutaneous active principle release implants over a prolonged period of time

Legal Events

Date Code Title Description
FB Suspension of granting procedure